|
1.
|
Danenberg PV: Thymidylate synthase - a
target enzyme in cancer chemotherapy. Biochem Biophys Acta.
473:73–92. 1977.
|
|
2.
|
Santi DV, MacHenry CS and Sommer H:
Mechanism of interaction of thymidylate synthetase with
5-fluorodeoxyuridylate. Biochemistry. 13:471–481. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Harada K, Kawashima Y, Yoshida H and Sato
M: Thymidylate synthase expression in oral squamous cell carcinoma
predicts response to S-1. Oncol Rep. 15:1417–1423. 2006.PubMed/NCBI
|
|
4.
|
Kawano K, Goto H, Kanda T and Yanagisawa
S: Predictive value of immunohistochemical thymidylate synthase
expression for histological response to tegafur/uracil (UFT) in
oral squamous cell carcinoma. Int J Oral Maxillofac Surg.
32:633–637. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Leichman CG, Lenz HJ, Leichman L, et al:
Quantitation of intratumoral thymidylate synthase expression
predicts for disseminated colorectal cancer response and resistance
to protracted-infusion fluorouracil and weekly leucovorin. J Clin
Oncol. 15:3223–3229. 1997.
|
|
6.
|
Beck A, Etienne MC, Chéradame S, et al: A
role for dihydropyrimidine dehydrogenase and thymidylate synthase
in tumor sensitivity to fluorouracil. Eur J Cancer. 30:1517–1522.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Lenz HJ, Leichman CG, Danenberg KD, et al:
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a
predictor for primary tumor response and overall survival. J Clin
Oncol. 14:176–182. 1996.PubMed/NCBI
|
|
8.
|
Hoque M, Kawamata H, Nakashiro K, et al:
Dihydropyrimidine dehydrogenase mRNA level correlates with the
response to 5-fluorouracil-based chemo-immuno-radiation therapy in
human oral squamous cell cancer. Int J Oncol. 19:953–958. 2001.
|
|
9.
|
Kobayashi H, Koike T, Nakatsuka A, et al:
Dihydropyrimidine dehydrogenase expression predicts survival
outcome and chemo-sensitivity to 5-fluorouracil in patients with
oral squamous cell carcinoma. Oral Oncol. 41:38–47. 2005.
View Article : Google Scholar
|
|
10.
|
Etienne MC, Chéradame S, Fischel JL, et
al: Response to fluorouracil therapy in cancer patients: the role
of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol.
13:1663–1670. 1995.PubMed/NCBI
|
|
11.
|
Yoshitomi I, Kawasaki G, Yanamoto S and
Mizuno A: Orotate phosphoribosyl transferase mRNA expression in
oral squamous cell carcinoma and its relationship with the
dihydropyrimidine dehydrogenase expression and the clinical effect
of 5-fluorouracil. Oral Oncol. 42:880–887. 2006. View Article : Google Scholar
|
|
12.
|
Peters GJ, Laurensse E, Leyva A, Lankelma
J and Pinedo HM: Sensitivity of human, murine, and rat cells to
5-fluorouracil and 5’-deoxy-5-fluorouridine in relation to
drug-metabolizing enzymes. Cancer Res. 46:20–28. 1986.
|
|
13.
|
Peters GJ, Braakhuis BJ, de Brujin EA,
Laurensse EJ, van Walsum M and Pinedo HM: Enhanced therapeutic
efficacy of 5’-deoxy-5-fluorouridine in 5-fluorouracil-resistant
head and neck tumors in relation to 5-fluorouracil metabolizing
enzymes. Br J Cancer. 56:327–334. 1989.
|
|
14.
|
Koizumi W, Saigenji K, Nakamaru N, Okayasu
I and Kurihara M: Prediction of response to 5’-deoxy-5fluorouridine
(5’-DFUR) in patients with inoperable advanced gastric cancer by
immunostaining of thymidine phosphorylase/platelet-derived
endothelial cell growth factor. Oncology. 56:215–222. 1999.
|
|
15.
|
Sawada N, Ishikawa T, Fukase Y, Nishida M,
Yoshikubo T and Ishitsuka H: Induction of thymidine phosphorylase
activity and enhancement of capecitabine efficacy by taxol/taxotere
in human cancer xenografts. Clin Cancer Res. 4:1013–1019.
1998.PubMed/NCBI
|
|
16.
|
Kawasaki G, Yoshitomi I, Yamamoto S and
Mizuno A: Thymidylate synthase and dihydropyrimidine dehydrogenase
expression in oral squamous cell carcinoma: An immunohistochemical
and clinicopathologic study. Oral Surg Oral Med Oral Pathol Radiol
Endod. 94:717–723. 2002. View Article : Google Scholar
|
|
17.
|
Yang CG, Ciccolini J, Blesius A, et al:
DPD-based adaptive dosing of 5-FU in patients with head and neck
cancer: impact on treatment efficacy and toxicity. Cancer Chemother
Pharmacol. 67:49–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Freedman ND, Schatzkin A, Leitzmann MF,
Hollenbeck AR and Abent CC: Alcohol and head and neck cancer risk
in a prospective study. Br J Cancer. 96:1469–1474. 2007.PubMed/NCBI
|
|
19.
|
Browman GP, Wong G, Hodson I, et al:
Influence of cigarette smoking on the efficacy of radiation therapy
in head and neck cancer. N Engl J Med. 328:159–163. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Yoshida Y, Komatsu M, Ozeki A, Nango R and
Tsukamoto I: Ethanol represses thymidylate synthase and thymidine
kinase at mRNA level in regenerating rat liver after partial
hepatectomy. Biochim Biophys Acta. 1336:180–186. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Lieber CS: Ethanol metabolism, cirrhosis
and alcoholism. Clin Chim Acta. 257:59–84. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Yamashita T, Toida M, Kato K, et al: The
effect of neoadjuvant therapy on the 5-fluorouracil metabolic and
relative enzymes of oral squamous cell carcinoma. Oncol Rep.
22:501–507. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Zevin S and Benowitz NL: Drug interactions
with tobacco smoking. An update. Clin Pharmacokinet. 36:425–438.
1999. View Article : Google Scholar : PubMed/NCBI
|
